Comparison of therapeutic effect of Melatonin, Metformin and Ursodeoxycholic acid with placebo in treatment of patients with Nonalcoholic Fatty Liver Disease (NAFLD)
Not Applicable
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD)K 76.0onalcoholic Fatty Liver Disease (NAFLD).
- Registration Number
- IRCT201407201155N21
- Lead Sponsor
- Vice chancellor for research of Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have proven statuses by Fibro Scan. Exclusion criteria: Consumption more than 20 gram of alcohol per day for women or more than 30 gram in men for at least 3 consecutive months during five last years; patients with hepatitis B, C and other chronic liver diseases including autoimmune liver diseases; patients with heart failure according to the history and clinical signs; patients who take medication causing osteohepatitis such as Tamoxifen, Amiodarone; patients with established diabetes mellitus; patients with established hemochromatosis; dissatisfaction for participate in study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum levels of liver enzymes. Timepoint: initially and three months later. Method of measurement: Laboratory Kit.;Steatosis. Timepoint: initially and three months later. Method of measurement: using fibroscan.
- Secondary Outcome Measures
Name Time Method Serum Lipids. Timepoint: Initially and three months later. Method of measurement: Laboratory Kit.;Body Mass Index. Timepoint: Initially and three months later. Method of measurement: with Seca Scale.